– the leading provider of online annual reports to individual and institutional investors.

Insite Vision Inc.

InSite Vision develops novel topical anti-infective products, including AzaSite. InSite is pursuing the expansion of its portfolio of anti-infective ophthalmic products to include ISV-502 in Phase 3 pivotal trials as a product candidate directed at treating eye and eye lid infections and inflammation, currently an unmet need. In addition, InSite is evaluating the use of its product platform for ear infections with the product candidate, AzaSite Otic(TM) in preclinical development. The company is also developing AzaSite Xtra, a product designed to assist in penetrating international markets.

No investor fact sheets added yet
No responsibility reports added yet

Browse Reports